Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7 — Stella

Home/Gestational Trophoblastic Neoplasia/Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

View on ClinicalTrials.gov

Recruiting

Back to Gestational Trophoblastic Neoplasia trials

Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Peking Union Medical College Hospital

Collaborators

Obstetrics & Gynecology Hospital of Fudan University, Shengjing Hospital

Enrollment target

~17 participants

Started

December 2024

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 60 Years

Sex

Female only

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.